Five different chicken B-LB genes were cloned and sequenced. The comparison of these sequences shows that they can be classified as members of two different families, the B-LBII family (containing the B-LBI and B-LBII genes) and the B-LBIII family (containing the B-LBIII, B-LBIV, and B-LBV genes). The extent of polymorphism within each of these families was assessed by in vitro amplification of DNA fragments encompassing exon 2 in several haplotypes. The nucleotide sequences were determined, and pairwise relationships were evaluated. In the course of this work, a sixth gene termed B-LBVI was identified, defining a third family (B-LBVI family). Polymorphism of the B-LBIII or B-LBVI families is far less extensive than that of the B-LBII family. In this latter, the distribution of conserved and polymorphic residues is similar to what has been described in mammals. These families seem to have been generated by gene duplication events giving rise to several isotypes, as observed in mammals. However, phylogenetic analyses indicate that these families are not homologous to their mammalian counterparts. Evaluation of the level of transcription of these different genes showed that genes from the B-LBII family are predominantly transcribed over those of the other families.

Glioblastoma is the most common primary brain tumor in human adults. Since existing treatments are not effective enough, novel therapeutic targets must be sought. The heparin-binding growth factor, heparin affin regulatory peptide (HARP), also known as pleiotrophin (PTN), could potentially represent such a target. We have previously shown that a mutant protein, HARPD111-136, which lacks HARP's C-terminal 26 amino acids, acts as a dominant negative HARP effector by heterodimerizing with the wild-type growth factor. The aim of our study was to evaluate the potential inhibitory activity of HARPD111-136 on the U87 MG human glioblastoma cell line. By overexpressing the truncated form of HARP in stably established clones of U87 MG cells, we observed an inhibition of proliferation under both anchorage-dependent and anchorage-independent conditions. We confirmed these results in an in vivo subcutaneous tumor xenograft model. In addition, we found that HARPD111-136 inhibited cell proliferation in a paracrine manner. Analysis of key cellular pathways revealed a decrease of cell adhesion in U87 MG cells that overexpressed the mutant protein, which could explain this inhibitory effect. A replication-defective adenovirus model that encoded HARPD111-136 supported a putative antiproliferative role for the truncated protein in vitro and in vivo. Interestingly, HARPD111-136 was also able to abolish angiogenic activity in HUVEC proliferation and in a Matrigel plug assay. These results demonstrate that considering its antiproliferative and angiostatic effects, HARPD111-136 could be of great interest when used in conjunction with standard treatments.Glioblastoma is the most common primary brain tumor in adult humans, with a median survival time of 12 months from the time of diagnosis, despite using standard therapeutic approaches (surgery, radiation and chemotherapy). A proper understanding of the principal pathways implicated in glioblastoma progression is needed to identify potential therapeutic targets. The heparin-binding growth factor, heparin affin regulatory peptide (HARP), also known as pleiotrophin (PTN) and heparin-binding growth-associated molecule (HB-GAM), could represent 1 such potential target.HARP is a 136-amino acid secreted polypeptide that forms with the protein midkine (MK), a 2-member family of heparin-binding growth factors. HARP is a developmentally regulated cytokine that is highly expressed in the embryonic nervous system, but its expression drops markedly after the perinatal phase and during adulthood. However, HARP expression may be deregulated, and HARP has been shown to be overexpressed in various tumor cell lines and primary human tumors, 1-3 including glioblastomas. In vitro, HARP displays a variety of biological activities including mitogenesis, angiogenesis, neurite outgrowth and cell migration. 4 Transforming activity has also been demonstrated for HARP when it is overexpressed in nontumor cell lines, such as NIH 3T3. 5Two transmembrane proteins with intracellular catalytic domains have been descri...

Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthesis of catecholamines. We describe here the isolation of the chicken TH gene and the analysis of 3 kb of its 5' flanking region. The chicken TH transcription unit spans 19 kb. The 60-bp proximal promoter contains a TATA box and a cyclic AMP response element (CRE) sequence. The 5' flanking region contains several AP1-, AP2-, and octamer-like sequences as well as a glucocorticoid response element at position -1.4 kb. A construct containing the 3-kb 5' flanking DNA fused to the chloramphenicol acetyltransferase (CAT) gene was transiently transfected into PC12 cells, and the effect of various effectors was tested. Only forskolin increased the CAT activity, likely owing to the presence of the CRE sequence. Constructs prepared by progressively deleting the 5' flanking DNA were transfected into PC12 and QT6 (quail transformed fibroblasts) cells. In both cell types, the transcriptional activity increased with deletion of the 5' flanking region. These results show that the 60-bp region containing the TATA box and the CRE is sufficient to act as a constitutive promoter for the chicken TH gene and that this region appears to be negatively controlled by upstream sequences.